3D Medicines Inc

HKSE:01244 (China)  
HK$ 6.30 (-1.1%) Jun 5
At Loss
P/B:
1.59
Market Cap:
HK$ 1.63B ($ 208.28M)
Enterprise V:
HK$ 859.95M ($ 110.12M)
Volume:
561.50K
Avg Vol (2M):
1.51M
Volume:
561.50K
At Loss
Avg Vol (2M):
1.51M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for 3D Medicines Inc ( HKSE:01244 ) from 2022 to Jun 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. 3D Medicines stock (HKSE:01244) PE ratio as of Jun 05 2024 is 0. More Details

3D Medicines Inc (HKSE:01244) PE Ratio (TTM) Chart

To

3D Medicines Inc (HKSE:01244) PE Ratio (TTM) Historical Data

Total 352
  • 1
  • 2
  • 3
  • 4
3D Medicines PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-05 At Loss 2024-03-27 At Loss
2024-06-04 At Loss 2024-03-26 At Loss
2024-06-03 At Loss 2024-03-25 At Loss
2024-05-31 At Loss 2024-03-22 At Loss
2024-05-30 At Loss 2024-03-21 At Loss
2024-05-29 At Loss 2024-03-20 At Loss
2024-05-28 At Loss 2024-03-19 At Loss
2024-05-27 At Loss 2024-03-18 At Loss
2024-05-24 At Loss 2024-03-15 At Loss
2024-05-23 At Loss 2024-03-14 At Loss
2024-05-22 At Loss 2024-03-13 At Loss
2024-05-21 At Loss 2024-03-12 At Loss
2024-05-20 At Loss 2024-03-11 At Loss
2024-05-17 At Loss 2024-03-08 At Loss
2024-05-16 At Loss 2024-03-07 At Loss
2024-05-14 At Loss 2024-03-06 At Loss
2024-05-13 At Loss 2024-03-05 At Loss
2024-05-10 At Loss 2024-03-04 At Loss
2024-05-09 At Loss 2024-03-01 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-06 At Loss 2024-02-27 At Loss
2024-05-03 At Loss 2024-02-26 At Loss
2024-05-02 At Loss 2024-02-23 At Loss
2024-04-30 At Loss 2024-02-22 At Loss
2024-04-29 At Loss 2024-02-21 At Loss
2024-04-26 At Loss 2024-02-20 At Loss
2024-04-25 At Loss 2024-02-19 At Loss
2024-04-24 At Loss 2024-02-16 At Loss
2024-04-23 At Loss 2024-02-15 At Loss
2024-04-22 At Loss 2024-02-14 At Loss
2024-04-19 At Loss 2024-02-09 At Loss
2024-04-18 At Loss 2024-02-08 At Loss
2024-04-17 At Loss 2024-02-07 At Loss
2024-04-16 At Loss 2024-02-06 At Loss
2024-04-15 At Loss 2024-02-05 At Loss
2024-04-12 At Loss 2024-02-02 At Loss
2024-04-11 At Loss 2024-02-01 At Loss
2024-04-10 At Loss 2024-01-31 At Loss
2024-04-09 At Loss 2024-01-30 At Loss
2024-04-08 At Loss 2024-01-29 At Loss
2024-04-05 At Loss 2024-01-26 At Loss
2024-04-03 At Loss 2024-01-25 At Loss
2024-04-02 At Loss 2024-01-24 At Loss
2024-03-28 At Loss 2024-01-23 At Loss

3D Medicines Inc (HKSE:01244) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.